Analysis and operational playbooks for biotech VPs of Clinical, Heads of Clinical Ops, and Medical Affairs leaders evaluating Brazilian sites. Grounded in the SambaTrials Q2 2026 landscape scan — 582 trials, 141 sponsors.
The structural case for Brazil — scale, cost, a transformed regulatory clock — weighed honestly against the operational catches: lab-assay availability, per-shipment importation, depot coverage, customs, and import valuation. Each one paired with the plan-ahead fix.
582 trials, 141 sponsors, 4.4× growth in three years, 60% Phase 3. What the shape of the Brazilian industry-trial market means for biotech VPs planning 2026-2027 programs.
Historical 9-12 months is now targeting ~6 under Lei 14.874/2024. Walk through RDC 9/2015, the new law, CEP, CONEP, and ANVISA — plus the parallel-submission strategy that actually hits the shorter window.
HCPA (53), FAMERP (35), São Lucas PUCRS (30), Liga Norte Riograndense (29), Barretos (18). Named centers, volume counts, and TA strengths across academic, private-academic, and dedicated research-center models.
São Paulo (454 trial-site records) vs. Porto Alegre (350). Dense metro scale vs. tight academic cluster. Methodology note on city-vs-state counts included. When to prefer which — and how good protocols use both.
A senior-consultant's pre-CRO checklist. TA fit, comparator access, lab thresholds, timeline impact, population demographics, biospecimen export, and who on your team actually owns the Brazilian arm.